Table 1.

Pneumocystis jirovecii Detection Criteria^a [31]

Proven P. jirovecii
Direct detection of the organism	Detection of the organism microscopically in tissue, BAL fluid, expectorated sputum using conventional or immunofluorescence staining
Probable P. jiroveciib
Host factors	CD4 count <200 cells/mm3
	Exposure to a medication with known anti-T-cell effects (antineoplastic, anti-inflammatory, or immunosuppressive)
	≥2 wk of prednisone equivalent dosing ≥0.3 mg/kg in the past 60 d
	Solid organ transplant
Clinical features	Radiographic features: particularly bilateral ground glass opacities, nodules, consolidations, cystic lesions, etc.
	Respiratory symptoms accompany radiographic abnormalities: nodules, infiltrates, effusions, etc.
Mycologic evidence	Detection of β−D-glucan ≥80 ng/L in >2 consecutive serum samples, provided exclusion of other etiologies
	PCR detection of Pneumocystis jirovecii

Abbreviations: BAL, bronchoalveolar lavage; PCR, polymerase chain reaction.

^aTable adapted from Donnelly et al. for the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium.

^bMust meet at least 1 criterion from each of the 3 categories.